Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab (CFZ533) in Moderately Active Proliferative Lupus Nephritis
NCT03610516Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2018
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing Iscalimab + SoC with Placebo + SoC (2 arms). Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 49 weeks and Ratio to Baseline in Urinary Protein Creatinine Ratio (UPCR) at Day 169. Started Sep 2018; status: completed.
02
Drugs
iscalimab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT03610516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610516.